Citations Please use one of the following formats to cite this article in your essay, paper or report: APA Sahi, Akshima
Cardiovascular outcomes trials such as LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) have shown that certain GLP-1 receptor agonists significantly reduce major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors
2023;111(14):2201e22174
I now feel that my cravings are under control
it does not license a numerical human safety factor, and any framing that converts no lethal dose in rodents into very safe in humans is smuggling in an inference the data do not support
By use-case framing, the market is classified into weight management and cardiovascular risk anchored indications